← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
RA Capital Nexus Fund II, L.P.
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001825376
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 3
- Purchases · 24M
- 7
- Average purchase
- $23.2M
- Median purchase
- $25.3M
- Gross purchase value
- $162.5M
Companies: Climb Bio, Inc. | Hemab Therapeutics Holdings, Inc. | Janux Therapeutics, Inc. | PepGen Inc. | Werewolf Therapeutics, Inc.
7 SEC accession(s) · 7 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. | COAG | Director | $52.2M | Open filing |
| 2026-01-07 | Climb Bio, Inc. | CLYM | Director | $24.9K | Open filing |
| 2025-12-15 | Climb Bio, Inc. | CLYM | Director | $754.7K | Open filing |
| 2025-09-30 | PepGen Inc. | PEPG | Director | $30.0M | Open filing |
| 2025-05-14 | Werewolf Therapeutics, Inc. | HOWL | Director | 10% Owner | $487.2K | Open filing |
| 2025-03-07 | Janux Therapeutics, Inc. | JANX | Director | $25.3M | Open filing |
| 2024-10-22 | Janux Therapeutics, Inc. | JANX | Director | $53.7M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 2/4
- Large purchase ≥ $100k
- 6/7
- Cluster buying · 15D
- 7/7
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.